Obatoclax regulates the proliferation and fusion of osteoclast precursors through the inhibition of ERK activation by RANKL

Molecules and Cells

Volumn 38, Issue 3, 2013, Pages 279-284

  Oh, Ju Hee ^a   Lee, Jae Yoon ^a   Park, Jin Hyeong ^a   No, Jeong Hyeon ^a   Lee, Na Kyung ^a  

^a Soonchunhyang University   (South Korea)

Author keywords

ERK1 2 MAP kinase; Fusion; Obatoclax; Osteoclast precursors; Proliferation

Indexed keywords

2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; CTSK PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MITOGEN ACTIVATED PROTEIN KINASE P38; OBATOCLAX; OSTEOCLAST DIFFERENTIATION FACTOR; PROTEIN; PROTEIN C FOS; STRESS ACTIVATED PROTEIN KINASE 1; TRAP PROTEIN; UNCLASSIFIED DRUG; 2-(2-AMINO-3-METHOXYPHENYL)-4H-1-BENZOPYRAN-4-ONE; ATP6V0D2 PROTEIN, MOUSE; DC-STAMP PROTEIN, MOUSE; ENZYME INHIBITOR; FLAVONOID; MEMBRANE PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE; NERVE PROTEIN; PROTON TRANSPORTING ADENOSINE TRIPHOSPHATE SYNTHASE; PYRROLE DERIVATIVE; TNFSF11 PROTEIN, MOUSE;

ANIMAL CELL; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; CELL FUSION; CELL PROLIFERATION; CONTROLLED STUDY; DOWN REGULATION; ENZYME ACTIVATION; ENZYME INHIBITION; GENE EXPRESSION; IN VITRO STUDY; MARKER GENE; MONONUCLEAR CELL; MOUSE; MULTINUCLEAR CELL; NONHUMAN; OSTEOCLAST; OSTEOCLASTOGENESIS; SIGNAL TRANSDUCTION; ANIMAL; C57BL MOUSE; CELL CULTURE; DRUG EFFECTS; GENE SILENCING; GENETICS; METABOLISM; PHYSIOLOGY;

ANIMALS; APOPTOSIS; CELL FUSION; CELL PROLIFERATION; CELLS, CULTURED; DOWN-REGULATION; ENZYME INHIBITORS; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; FLAVONOIDS; GENE EXPRESSION; GENE SILENCING; MAP KINASE SIGNALING SYSTEM; MEMBRANE PROTEINS; MICE, INBRED C57BL; NERVE TISSUE PROTEINS; OSTEOCLASTS; PYRROLES; RANK LIGAND; VACUOLAR PROTON-TRANSLOCATING ATPASES;

EID: 84962198343     PISSN: 10168478     EISSN: 02191032     Source Type: Journal    
DOI: 10.14348/molcells.2015.2340     Document Type: Article

References (36)

1. Anderson, D. M., Maraskovsky, E., Billingsley, W. L., Dougall, W. C., Tometsko, M. E., Roux, E. R., Teepe, M. C., DuBose, R. F., Cosman, D., and Galibert, L. (1997). A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function. Nature 390, 175-179.
2. Blair, H. C. (1998). How the osteoclast degrades bone. Bioessays 20, 837-848.
3. Boyle, W. J., Simonet, W. S., and Lacey, D. L. (2003). Osteoclast differentiation and activation. Nature 423, 337-342.
4. CampaCs, C., Cosialls, A. M., Barragán, M., Iglesias-Serret, D., Santidrián, A. F., Coll-Mulet, L., de Frias, M., Domingo, A., Pons, G., and Gil, J. (2006). Bcl-2 inhibitors induce apoptosis in chronic lymphocytic leukemia cells. Exp. Hematol. 34, 1663-1669.
5. Choi, J., Choi, S. Y., Lee, S. Y., Lee, J. Y., Kim, H. S., Lee, S. Y., and Lee, N. K. (2013). Caffeine enhances osteoclast differentiation and maturation through p38 MAP kinase/Mitf and DCSTAMP/CtsK and TRAP pathway. Cell. Signal. 25, 1222-1227.
6. David, J. P., Sabapathy, K., Hoffmann, O., Idarraga, M. H., and Wagner, E. F. (2002). JNK1 modulates osteoclastogenesis through both c-Jun phosphorylation-dependent and-independent mechanisms. J. Cell Sci. 115, 4317-4325.
7. de Vries, T. J., Schoenmaker, T., Beertsen, W., van der Neut, R., and Everts, V. (2005). Effect of CD44 deficiency on in vitro and in vivo osteoclast formation. J. Cell. Biochem. 94, 954-966.
8. Harada, S., and Rodan, G. A. (2003). Control of osteoblast function and regulation of bone mass. Nature 423, 349-355.
9. Hartgers, F. C., Vissers, J. L., Looman, M. W., van Zoelen, C., Huffine, C., Figdor, C. G., and Adema, G. J. (2000). DC-STAMP, a novel multimembrane-spanning molecule preferentially expressed by dendritic cells. Eur. J. Immunol. 30, 3585-3590.
10. Hockenbery, D. M., Oltvai, Z. N., Yin, X. M., Milliman, C. L., and Korsmeyer, S. J. (1993). Bcl-2 functions in an antioxidant pathway to prevent apoptosis. Cell 75, 241-251.
11. Hwang, J. J., Kuruvilla, J., Mendelson, D., Pishvaian, M. J., Deeken, J. F., Siu, L. L., Berger, M. S., Viallet, J., and Marshall, J. L. (2010). Phase I dose finding studies of obatoclax (GX15-070), a small molecule pan-BCL-2 family antagonist, in patients with advanced solid tumors or lymphoma. Clin. Cancer Res. 16, 4038-4045.
12. Ishii, M., Iwai, K., Koike, M., Ohshima, S., Kudo-Tanaka, E., Ishii, T., Mima, T., Katada, Y., Miyatake, K., Uchiyama, Y., and Saeki, Y. (2006). RANKL-induced expression of tetraspanin CD9 in lipid raft membrane microdomain is essential for cell fusion during osteoclastogenesis. J. Bone Miner. Res. 21, 965-976.
13. Kim, H. S., and Lee, N. K. (2014). Gene expression profiling in osteoclast precursors by insulin using microarray analysis. Mol. Cells 30, 827-832.
14. Kim, K., Lee, S. H., Kim, J., Choi, Y., and Kim, N. (2008). NFATc1 induces osteoclast fusion via upregulation of Atp6v0d2 and the dendritic cell-specific transmembrane protein (DCSTAMP). Mol. Endocrinol. 22, 176-185.
15. Kim, P. S., Jochems, C., Grenga, I., Donahue, R. N., Tsang, K. Y., Gulley, J. L., Schlom, J., and Farsaci, B. (2014). Pan-Bcl-2 Inhibitor, GX15-070 (Obatoclax), decreases human T regulatory lymphocytes while preserving effector T lymphocytes: a rationale for its use in combination immunotherapy, J. Immunol. 192, 2622-2633.
16. Konopleva, M., Watt, J., Contractor, R., Tsao, T., Harris, D., Estrov, Z., Bornmann, W., Kantarjian, H., Viallet, J., Samudio, I., et al. (2008). Mechanisms of antileukemic activity of the novel Bcl-2 homology domain-3 mimetic GX15-070 (obatoclax). Cancer Res. 68, 3413-3420.
17. Kukita, T., Wada, N., Kukita, A., Kakimoto, T., Sandra, F., Toh, K., Nagata, K., Iijima, T., Horiuchi, M., Matsusaki, H., et al. (2004). RANKL-induced DC-STAMP is essential for osteoclastogenesis. J. Exp. Med. 200, 941-946.
18. Lee, J. Y., and Lee, N. K. (2014). Up-regulation of cyclinD1 and Bcl2A1 by insulin is involved in osteoclast proliferation. Life Sci. 114, 57-61.
19. Lee, S. H., Rho, J., Jeong, D., Sul, J. Y., Kim, T., Kim, N., Kang, J. S., Miyamoto, T., Suda, T., Lee, S. K., et al. (2006). v-ATPase V0 subunit d2-deficient mice exhibit impaired steoclast fusion and increased bone formation. Nat. Med. 12, 1403-1409.
20. Li, X., Udagawa, N., Itoh, K., Suda, K., Murase, Y., and Nishihara, T. (2002). p38 MAPK-mediated signals are required for inducing osteoclast differentiation but not for osteoclast function. Endocrinology 143, 3105-3113.
21. Mansky, K. C., Sankar, U., Han, J., and Ostrowski, M. C. (2002). Microphthalmia transcription factor is a target of the p38 MAPK pathway in response to receptor activator of NF-B ligand signaling. J. Biol. Chem. 277, 11077-11083.
22. Nishi, T., Kawasaki-Nishi, S., and Forgac, M. (2003). Expression and function of the mouse V-ATPase d subunit isoforms. J. Biol. Chem. 278, 46396-46402.
23. Paik, P. K., Rudin, C. M., Brown, A., Rizvi, N. A., Takebe, N., Travis, W., James, L., Ginsberg, M. S., Juergens, R., Markus, S., et al. (2010). A phase I study of obatoclax mesylate, a Bcl-2 antagonist, plus topotecan in solid tumor malignancies. Cancer Chemother. Pharmacol. 66, 1079-1085.
24. Rho, J., Altmann, C. R., Socci, N. D., Merkov, L., Kim, N., So, H., Lee, O., Takami, M., Brivanlou, A. H., and Choi, Y. (2002). Gene expression profiling of osteoclast differentiation by combined suppression subtractive hybridization (SSH) and cDNA microarray analysis. DNA Cell. Biol. 21, 541-549.
25. Rodan, G. A., and Martin, T. J. (2000) Therapeutic approaches to bone diseases. Science 289, 1508-1514.
26. Staege, H., Brauchlin, A., Schoedon, G., and Schaffner, A. (2001). Two novel genes FIND and LIND differentially expressed in deactivated and Listeria-infected human macrophages. Immunogenetics 53, 105-113.
27. Teitelbaum, S. L. (2000). Bone resorption by osteoclasts. Science 289, 1504-1508.
28. Trudel, S., Li, Z. H., Rauw, J., Tiedemann, R. E., Wen, X. Y., and Stewart, A. K. (2007). Preclinical studies of the pan-Bcl inhibitor obatoclax (GX015-070) in multiple myeloma. Blood 109, 5430-5438.
29. Vignery, A. (2000). Osteoclasts and giant cells: macrophagemacrophage fusion mechanism. Int. J. Exp. Pathol. 81, 291-304.
30. Wei, S., Wang, M. W., Teitelbaum, S. L., and Ross, F. P. (2002). Interleukin-4 reversibly inhibits osteoclastogenesis via inhibition of NF-kappa B and mitogen-activated protein kinase signaling. J. Biol. Chem. 277, 6622-6630.
31. Wong, B. R., Josien, R., Lee, S. Y., Sauter, B., Li, H. L., Steinman, R. M., and Choi, Y. (1997). TRANCE (tumor necrosis factor [TNF]-related activation-induced cytokine), a new TNF family member predominantly expressed in T cells, is a dendritic cellspecific survival factor. J. Exp. Med. 186, 2075-2080.
32. Wu, H., Xu, G., and Li, Y. P. (2009). Atp6v0d2 is an essential component of the osteoclast-specific proton pump that mediates extracellular acidification in bone resorption. J. Bone Miner. Res. 24, 871-885.
33. Xing, L., Xiu, Y., and Boyce, B. F. (2012). Osteoclast fusion and regulation by RANKL-dependent and independent factors. World J. Orthop. 3, 212-222.
34. Yamashita, J., Datta, N. S., Chun, Y. H., Yang, D. Y., Carey, A. A., Kreider, J. M., Goldstein, S. A., and McCauley, L. K. (2008). Role of Bcl2 in osteoclastogenesis and PTH anabolic actions in bone. J. Bone Miner. Res. 23, 621-632.
35. Yang, J., Zhang, X., Wang, W., and Liu, J. (2010). Insulin stimulates osteoblast proliferation and differentiation through ERK and PI3K in MG-63 cells. Cell Biochem. Funct. 28, 334-341.
36. Zhang, C., Dou, C. E., Xu, J., and Dong, S. (2014). DC-STAMP, the key fusion-mediating molecule in osteoclastogenesis. J. Cell. Physiol. 229, 1330-1335.